Adjuvant chemotherapy of osteogenic sarcoma: progress and perspectives
Frei, E.; Jaffe, N.; Gero, M.; Skipper, H.; Watts, H.
Journal of the National Cancer Institute 60(1): 3-10
1978
ISSN/ISBN: 0027-8874 PMID: 304894 Document Number: 131572
It is increasingly in the nature of clinical therapeutic research in oncology that the definitive evaluation of a new treatment program requires a lengthy follow-up period, often several years. This is particularly true of adjuvant studies and adjuvant chemotherapy studies in OGS programs, demonstrated a similar response rate. MTX, because it is myelosuppressive, was used intermittently at 3-wk intervals to allow for recovery from myelosuppression. With proper monitoring of the pharmacology of MTX and of renal function and with the use of fluids and alkali, myelosuppression with high-dose MTX-CF occurs infrequently, and it was possible to deliver this program on a weekly basis. Consistent with experimental evidence for a steep dose-response curve for MTX, this program produced an objective response in over 80% of patients with overt OGS. The 1st adjuvant program for OGS involved high-dose MTX-CF every 3 wk and vincristine as a priming dose. Adriamycin was added in the 2nd protocol.